| Ditan | |
|---|---|
| Drug class | |
 Lasmiditan | |
| Class identifiers | |
| Use | Migraine |
| Biological target | 5-HT1F receptor |
| Legal status | |
| In Wikidata | |
Ditans are a class of abortive medication for the treatment of migraines. [1] The first ditan, Eli Lilly's lasmiditan, was approved by the FDA in 2019.
Ditans selectively bind to the 5-HT1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT1B and 5-HT1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible patients, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction. [2] A 1998 review has found such side effects to rarely occur in most patients taking triptans. [3] [4]
One clinical trial showed that 200 mg lasmiditan provided pain freedom by 2 hours in 32% of individuals with migraine attacks of moderate or severe intensity, and 100 mg lasmiditan did so in 28%, compared with 15% after a placebo. [5] Subsequently, these results were confirmed in another trial. [6]
- ^ Qubty W, Patniyot I (2020). "Migraine Pathophysiology". Headache. 107: 1–6. doi: 10.1016/j.pediatrneurol.2019.12.014. PMID 32192818. S2CID 221753230.
- ^ "Molecule of the Month July 2010: Lasmiditan hydrochloride". Prous Science. Retrieved 2011-08-03.
- ^ Dahlöf CG, Mathew N (1998). "Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?". Cephalalgia: An International Journal of Headache. 18 (8): 539–45. doi: 10.1046/j.1468-2982.1998.1808539.x. PMID 9827245. S2CID 30125923.
- ^ Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M. Arzneimittelwirkungen. Wissenschaftliche Verlagsgesellschaft.
- ^ Kuca B, Silberstein SD, Wietecha L, Berg PH (December 11, 2018). "Lasmiditan is an effective acute treatment for migraine: a phase 3 randomised stuty". Neurology. 91 (24): e2222–e2232. doi: 10.1212/WNL.0000000000006641. PMC 6329326. PMID 30446595.
- ^ Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C (Jul 1, 2019). "Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine". Brain. 142 (7): 1894–1904. doi: 10.1093/brain/awz134. PMC 6620826. PMID 31132795.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
| Ditan | |
|---|---|
| Drug class | |
|
Lasmiditan | |
| Class identifiers | |
| Use | Migraine |
| Biological target | 5-HT1F receptor |
| Legal status | |
| In Wikidata | |
Ditans are a class of abortive medication for the treatment of migraines. [1] The first ditan, Eli Lilly's lasmiditan, was approved by the FDA in 2019.
Ditans selectively bind to the 5-HT1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT1B and 5-HT1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible patients, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction. [2] A 1998 review has found such side effects to rarely occur in most patients taking triptans. [3] [4]
One clinical trial showed that 200 mg lasmiditan provided pain freedom by 2 hours in 32% of individuals with migraine attacks of moderate or severe intensity, and 100 mg lasmiditan did so in 28%, compared with 15% after a placebo. [5] Subsequently, these results were confirmed in another trial. [6]
- ^ Qubty W, Patniyot I (2020). "Migraine Pathophysiology". Headache. 107: 1–6. doi: 10.1016/j.pediatrneurol.2019.12.014. PMID 32192818. S2CID 221753230.
- ^ "Molecule of the Month July 2010: Lasmiditan hydrochloride". Prous Science. Retrieved 2011-08-03.
- ^ Dahlöf CG, Mathew N (1998). "Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?". Cephalalgia: An International Journal of Headache. 18 (8): 539–45. doi: 10.1046/j.1468-2982.1998.1808539.x. PMID 9827245. S2CID 30125923.
- ^ Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M. Arzneimittelwirkungen. Wissenschaftliche Verlagsgesellschaft.
- ^ Kuca B, Silberstein SD, Wietecha L, Berg PH (December 11, 2018). "Lasmiditan is an effective acute treatment for migraine: a phase 3 randomised stuty". Neurology. 91 (24): e2222–e2232. doi: 10.1212/WNL.0000000000006641. PMC 6329326. PMID 30446595.
- ^ Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C (Jul 1, 2019). "Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine". Brain. 142 (7): 1894–1904. doi: 10.1093/brain/awz134. PMC 6620826. PMID 31132795.
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |